🎉 M&A multiples are live!
Check it out!

Shanghai Allist Valuation Multiples

Discover revenue and EBITDA valuation multiples for Shanghai Allist and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Shanghai Allist Overview

About Shanghai Allist

Shanghai Allist Pharmaceuticals Co Ltd is an innovative drug company in the field of cancer treatment.


Founded

2004

HQ

China
Employees

n/a

Website

allist.com.cn

Financials

LTM Revenue $527M

LTM EBITDA $224M

EV

$5.0B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Shanghai Allist Financials

Shanghai Allist has a last 12-month revenue of $527M and a last 12-month EBITDA of $224M.

In the most recent fiscal year, Shanghai Allist achieved revenue of $278M and an EBITDA of $95.9M.

Shanghai Allist expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Shanghai Allist valuation multiples based on analyst estimates

Shanghai Allist P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $278M $489M XXX XXX XXX
Gross Profit $72.3M $105M XXX XXX XXX
Gross Margin 26% 21% XXX XXX XXX
EBITDA $95.9M $212M XXX XXX XXX
EBITDA Margin 34% 43% XXX XXX XXX
Net Profit $2.5M $18.0M XXX XXX XXX
Net Margin 1% 4% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Shanghai Allist Stock Performance

As of April 15, 2025, Shanghai Allist's stock price is CNY 88 (or $12).

Shanghai Allist has current market cap of CNY 39.5B (or $5.4B), and EV of CNY 36.5B (or $5.0B).

See Shanghai Allist trading valuation data

Shanghai Allist Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$5.0B $5.4B XXX XXX XXX XXX $0.46

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Shanghai Allist Valuation Multiples

As of April 15, 2025, Shanghai Allist has market cap of $5.4B and EV of $5.0B.

Shanghai Allist's trades at 9.5x LTM EV/Revenue multiple, and 22.4x LTM EBITDA.

Analysts estimate Shanghai Allist's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Shanghai Allist and 10K+ public comps

Shanghai Allist Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $5.0B XXX XXX XXX
EV/Revenue 10.3x XXX XXX XXX
EV/EBITDA 23.7x XXX XXX XXX
P/E 28.0x XXX XXX XXX
P/E/Growth 1.3x XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Shanghai Allist Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Shanghai Allist Valuation Multiples

Shanghai Allist's NTM/LTM revenue growth is 25%

Shanghai Allist's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Shanghai Allist's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Shanghai Allist's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Shanghai Allist and other 10K+ public comps

Shanghai Allist Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 76% XXX XXX XXX XXX
EBITDA Margin 43% XXX XXX XXX XXX
EBITDA Growth 121% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 69% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 30% XXX XXX XXX XXX
G&A Expenses to Revenue 3% XXX XXX XXX XXX
R&D Expenses to Revenue 16% XXX XXX XXX XXX
Opex to Revenue 68% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Shanghai Allist Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Shanghai Allist M&A and Investment Activity

Shanghai Allist acquired  XXX companies to date.

Last acquisition by Shanghai Allist was  XXXXXXXX, XXXXX XXXXX XXXXXX . Shanghai Allist acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Shanghai Allist

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Shanghai Allist

When was Shanghai Allist founded? Shanghai Allist was founded in 2004.
Where is Shanghai Allist headquartered? Shanghai Allist is headquartered in China.
Is Shanghai Allist publicy listed? Yes, Shanghai Allist is a public company listed on SHG.
What is the stock symbol of Shanghai Allist? Shanghai Allist trades under 688578 ticker.
When did Shanghai Allist go public? Shanghai Allist went public in 2020.
Who are competitors of Shanghai Allist? Similar companies to Shanghai Allist include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Shanghai Allist? Shanghai Allist's current market cap is $5.4B
What is the current revenue of Shanghai Allist? Shanghai Allist's last 12-month revenue is $527M.
What is the current EBITDA of Shanghai Allist? Shanghai Allist's last 12-month EBITDA is $224M.
What is the current EV/Revenue multiple of Shanghai Allist? Current revenue multiple of Shanghai Allist is 9.5x.
What is the current EV/EBITDA multiple of Shanghai Allist? Current EBITDA multiple of Shanghai Allist is 22.4x.
What is the current revenue growth of Shanghai Allist? Shanghai Allist revenue growth between 2023 and 2024 was 76%.
Is Shanghai Allist profitable? Yes, Shanghai Allist is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.